CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
1.750
-0.460 (-20.81%)
At close: Oct 29, 2026, 4:00 PM EDT
1.790
+0.040 (2.29%)
Pre-market: Oct 30, 2026, 8:34 AM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes CervoMed the 39,110th largest employer in the world and 5,704th in the United States.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$22,086
Profits / Employee
-$2,023,316
Market Cap
26.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Mar 31, 2023 | 4 | - | - |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 214 |
| Metagenomi Therapeutics | 113 |
| Aligos Therapeutics | 82 |
| IRulya Therapeutics | 38 |
| eXoZymes | 32 |
| Filana Therapeutics | 20 |
| Edesa Biotech | 17 |
| BriaCell Therapeutics | 16 |
CRVO News
- 23 hours ago - CervoMed announces publication of two articles supporting neflamapimod - TheFly
- 1 day ago - CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 18 days ago - CervoMed presents initial data from neflamapimod trial - TheFly
- 4 weeks ago - CervoMed neflamapimod update removes key overhang, says Jones - TheFly
- 4 weeks ago - CervoMed announces PK results with new neflamapimod oral tablet formula - TheFly
- 4 weeks ago - CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit - GlobeNewsWire
- 5 weeks ago - CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 6 weeks ago - CervoMed Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts